8/23/2021 12:28:08 PM - Pulled back from its 52-week high and it is consolidating near its 50 DMA line. Reported earnings +700% on +69% sales revenues for the Jun '21 quarter but fundamental concerns remain. It was dropped from the Featured Stocks list on 11/28/18.
7/29/2021 12:15:38 PM - Perched at its 52-week high after recently wedging higher with gains lacking great volume conviction. Reported earnings +69% on +19% sales revenues for the Mar '21 quarter but fundamental concerns remain. It was dropped from the Featured Stocks list on 11/28/18.
5/26/2020 12:33:46 PM - Rebounded above its 200 DMA line with volume-driven gains approaching its 52-week high. Reported earnings -19% on +4% sales revenues for the Mar '20 quarter and fundamental concerns remain. It was dropped from the Featured Stocks list on 11/28/18.
5/22/2020 12:40:38 PM - Rebounding above its 200 DMA line with big gains this week on higher volume. reported earnings -19% on +4% sales revenues for the Mar '20 quarter and fundamental concerns remain. It was dropped from the Featured Stocks list on 11/28/18.
11/28/2018 5:21:20 PM - Fell further below its 50 and 200 DMA lines with today's big loss on higher volume violating the recent low ($49.03 on 11/20/18) and raising more serious concerns. It will be dropped from the Featured Stocks list tonight. A rebound above the 50 DMA line is needed for its outlook to improve.
11/27/2018 6:24:05 PM - G - Volume totals have been cooling, but the longer it lingers below its 50 and 200 DMA lines the worse its outlook gets. Remains only -12.3% off its all-time high. More damaging losses below the recent low ($49.03 on 11/20/18) would raise serious concerns. See the latest FSU analysis for more details and a new annotated graph.
11/20/2018 1:08:55 PM - G - The longer it lingers below its 200 DMA line ($51.78) and its 50 DMA line ($53.03) the worse its outlook gets. Remains only -12.4% off its all-time high, but more damaging losses would raise serious concerns.
11/14/2018 5:29:22 PM - G - Sank below its 200 DMA line ($51.67) near the prior low with lighter volume behind today's 4th consecutive loss, finishing -12.8% off its all-time high. The prior low ($49.34 on 10/08/18) defines important near term support.
11/9/2018 1:13:41 PM - G - Reported earnings +30% on +12% sales revenues for the Sep '18 quarter. Gapped down and abruptly retreated below its 50 and 200 DMA lines with today's big loss triggering a technical sell signal and its color code is changed to green. Disciplined investors note it did not trigger a technical buy signal after previously noted - "Volume and volatility often increase near earnings news. Its 50 DMA line ($53.26) and 200 DMA line ($51.52) define near-term support. Subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal."
11/7/2018 5:09:19 PM - Y - Perched near its all-time high and its color code is changed to yellow. Due to report earnings after the market close on Thursday, November 8th, 2018. Volume and volatility often increase near earnings news. Its 50 DMA line ($53.26) and 200 DMA line ($51.52) define near-term support. Subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal.
11/1/2018 10:19:33 AM - G - Consolidating near its 50 DMA line ($52.98). Subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal.
10/25/2018 5:54:22 PM - G - Sputtering below its 50 DMA line ($52.91) after recent volume-driven losses hurt its outlook. A rebound and subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal.
10/19/2018 6:36:52 PM - G - Color code is changed to green after slumping back below its 50 DMA line ($52.88) with a volume-driven loss today hurting its outlook. A rebound and subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal.
10/16/2018 4:00:53 PM - Y - Halted its slide at its 200 DMA line and today's rebound above the 50 DMA line ($52.76) helped its outlook improve. Color code is changed to yellow. Subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal.
10/12/2018 6:04:14 PM - G - Halted its slide and stubbornly holding its ground this week at its 200 DMA line ($50.60). A rebound above the 50 DMA line ($52.73) is needed for its outlook to improve. Subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal.
10/9/2018 5:13:38 PM - G - Color code is changed to green after a slump. Halted its slide at its 200 DMA line, however a rebound above the 50 DMA line is needed for its outlook to improve. Subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal.
10/2/2018 6:10:48 PM - Y - Big loss today on higher volume was action indicative of distributional pressure. It was highlighted in yellow with pivot point cited based on its 6/06/18 high plus 10 cents in the 9/26/18 mid-day report. Subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter, its 2nd strong quarterly comparison above the +25% minimum guideline (C criteria). Annual earnings (A criteria) growth has been steady.
9/27/2018 11:25:01 AM - Y - Finished near the middle of its intra-day range after highlighted in yellow with pivot point cited based on its 6/06/18 high plus 10 cents in the prior mid-day report. Perched within close striking distance of its all-time high following volume-driven gains. Subsequent gains above the pivot point backed by more than +40% above average volume are needed to trigger a proper technical buy signal. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter, its 2nd strong quarterly comparison above the +25% minimum guideline (C criteria). Annual earnings (A criteria) growth has been steady. See the latest FSU analysis for more details and an annotated graph.
9/26/2018 6:35:17 PM - Y - Finished near the middle of its intra-day range after highlighted in yellow with pivot point cited based on its 6/06/18 high plus 10 cents in the earlier mid-day report. Challenging its all-time high with volume-driven gains. Subsequent gains above the pivot point backed by more than +40% above average volume may trigger a technical buy signal. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter, its 2nd strong quarterly comparison above the +25% minimum guideline (C criteria). Annual earnings (A criteria) growth has been steady. See the latest FSU analysis for more details and a new annotated graph.
9/26/2018 12:37:48 PM - Y - Color code is changed to yellow with pivot point cited based on its 6/06/18 high plus 10 cents. Rallying from support at its 50 DMA line and challenging its all-time high with volume-driven gains. Subsequent gains above the pivot point backed by more than +40% above average volume may trigger a technical buy signal. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter, its 2nd strong quarterly comparison above the +25% minimum guideline (C criteria). Annual earnings (A criteria) growth has been steady.
9/25/2018 12:51:52 PM - Prior mid-day reports noted while rallying from support at its 50 DMA line - "Faces little resistance up to the $57 level. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter, its 2nd strong quarterly comparison. Quarterly earnings increases in prior comparisons were below the +25% minimum guideline (C criteria).
9/24/2018 12:22:06 PM - Making its 2nd consecutive mid-day report appearance rallying from support at its 50 DMA line, it was previously noted - "Faces little resistance up to the $57 level. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter, its 2nd strong quarterly comparison. Quarterly earnings increases in prior comparisons were below the +25% minimum guideline (C criteria).
9/21/2018 12:32:19 PM - Rallying from support at its 50 DMA line, it faces little resistance up to the $57 level. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +38% on +14% sales revenues for the Jun '18 quarter, its 2nd strong quarterly comparison. Quarterly earnings increases in prior comparisons were below the +25% minimum guideline (C criteria).
8/30/2018 12:48:56 PM - Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. Meeting resistance when trying to rebound above its 50 DMA line. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +28% on +12% sales revenues for the Mar '18 quarter. Quarterly earnings increases in prior comparisons were below the +25% minimum guideline (C criteria).
8/2/2018 1:13:14 PM - Reported earnings +38% on +14% sales revenues for the Jun '18 quarter. Meeting resistance after rebounding above its 50 DMA line with today's early volume-driven gain. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +28% on +12% sales revenues for the Mar '18 quarter. Quarterly earnings increases in prior comparisons were below the +25% minimum guideline (C criteria).
6/27/2018 12:16:03 PM - Violating its 50 DMA line with today's big volume-driven loss. Last noted with caution in the 6/04/18 mid-day report - "Perched at its all-time high after wedged higher with a streak of gains lacking great volume conviction. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +28% on +12% sales revenues for the Mar '18 quarter. Quarterly earnings increases in prior comparisons were below the +25% minimum guideline (C criteria)."
6/4/2018 12:17:53 PM - Perched at its all-time high after wedged higher with a streak of gains lacking great volume conviction. The Medical - Products firm has technology to treat patients with spine disorders. Reported earnings +28% on +12% sales revenues for the Mar '18 quarter. Quarterly earnings increases in prior comparisons were below the +25% minimum guideline (C criteria).
4/23/2018 12:41:02 PM - Reversed into the red after hitting a new all-time high earlier today. Wedged higher with gains lacking great volume conviction after finding support at its 50 DMA line. Hailing from the very strong Medical - Products industry group, this firm has technology to treat patients with spine disorders. GMED was noted with caution in prior mid-day reports - "Reported earnings +23% on +16% sales revenues for the Dec '17 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
4/10/2018 12:23:36 PM - Consolidating near its all-time high, finding support at its 50 DMA line. Hailing from the very strong Medical - Products industry group, this firm has technology to treat patients with spine disorders. GMED was last noted with caution in the 2/26/18 mid-day report - "Reported earnings +23% on +16% sales revenues for the Dec '17 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
2/26/2018 12:29:22 PM - Consolidating near its all-time high hit last week. Reported earnings +23% on +16% sales revenues for the Dec '17 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria).
8/18/2017 1:18:17 PM - Consolidating below its 50 DMA line yet above its 200 DMA line. Reported earnings +10% on +11% sales revenues for the Jun '17 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria).
1/25/2016 12:07:04 PM - Consolidating near its 200 DMA line. Prior mid-day reports cautioned members - "Reported earnings +17% on +16% sales revenues for the Sep '15 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
1/8/2016 12:31:17 PM - Reported earnings +17% on +16% sales revenues for the Sep '15 quarter. Prior mid-day reports cautioned members - "Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
1/7/2016 12:34:55 PM - Reported earnings +17% on +16% sales revenues for the Sep '15 quarter. Prior mid-day reports cautioned members - "Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
11/12/2015 12:18:49 PM - Rebounding following a deep consolidation since last noted with caution in the 8/14/15 mid-day report - "Reported earnings +9% on +18% sales revenues for the Jun '15 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
8/14/2015 1:03:42 PM - Abruptly retreated from its 52-week high with volume-driven losses yet found support at its 50 DMA line all week. Prior mid-day reports repeatedly cautioned members - "Reported earnings +9% on +18% sales revenues for the Jun '15 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
8/7/2015 1:00:14 PM - Abruptly retreating from its 52-week high with volume-driven losses testing support at its 50 DMA line. Prior mid-day reports repeatedly cautioned members - "Reported earnings +9% on +18% sales revenues for the Jun '15 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
8/3/2015 12:19:22 PM - Abruptly retreating today after hitting new 52-week highs with a streak of 6 consecutive volume-driven gains. The 7/31/15 mid-day report cautioned members - "Reported earnings +9% on +18% sales revenues for the Jun '15 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria)."
7/31/2015 12:40:36 PM - Gapped up today hitting a new 52-week high. Reported earnings +9% on +18% sales revenues for the Jun '15 quarter. Quarterly earnings increases in the prior comparisons also were below the +25% minimum guideline (C criteria).
4/30/2014 12:08:45 PM - Rebounding near its 50 DMA line with today's gain, however that short-term average may act as resistance. Reported earnings +14% on +9% sales revenues for the Mar '14 quarter. Quarterly earnings increases in the 5 latest comparisons showed growth below the +25% minimum guideline (C criteria).
4/7/2014 12:52:26 PM - Consolidating near its 50 DMA line with today's 3rd consecutive loss on ever-increasing volume. Reported earnings +14% on +15% sales revenues for the Dec '13 quarter. The 1/16/14 mid-day report cautioned members - "Quarterly earnings increases in the 3 latest comparisons through Sep '13 showed growth below the +25% minimum guideline (C criteria)."
3/5/2014 12:27:41 PM - Hitting new 52-week highs with today's gain adding to a recent spurt of volume-driven gains. No resistance remains due to overhead supply. Reported earnings +14% on +15% sales revenues for the Dec '13 quarter. The 1/16/14 mid-day report cautioned members - "Quarterly earnings increases in the 3 latest comparisons through Sep '13 showed growth below the +25% minimum guideline (C criteria)."
3/4/2014 12:24:14 PM - Challenging its 52-week high with today's gain adding to a recent spurt of volume-driven gains. No resistance remains due to overhead supply. Reported earnings +14% on +15% sales revenues for the Dec '13 quarter. The 1/16/14 mid-day report cautioned members - "Quarterly earnings increases in the 3 latest comparisons through Sep '13 showed growth below the +25% minimum guideline (C criteria)."
2/27/2014 12:39:55 PM - Hitting a new 52-week high with today's 6th consecutive gain. No resistance remains due to overhead supply. Reported earnings +14% on +15% sales revenues for the Dec '13 quarter. Last noted in the 1/16/14 mid-day report with caution - "Quarterly earnings increases in the 3 latest comparisons through Sep '13 showed growth below the +25% minimum guideline (C criteria)."
1/16/2014 12:30:28 PM - Hitting new 52-week highs with today's 3rd consecutive gain, rallying this week with no resistance remaining due to overhead supply. Last noted in the 12/17/13 mid-day report with caution - "Quarterly earnings increases in the 3 latest comparisons through Sep '13 showed growth below the +25% minimum guideline (C criteria)."
12/17/2013 12:18:44 PM - Consolidating near its 52-week high with no resistance remaining due to overhead supply. Quarterly earnings increases in the 3 latest comparisons through Sep '13 showed growth below the +25% minimum guideline (C criteria).